A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor

J. H. Schiller, B. Storer, K. Tutsch, R. Arzoomanian, D. Alberti, C. Feierabend, D. Spriggs

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a novel antitubulin agent derived from the bark of the Pacific yew tree, may be one of the most active single agents in our chemotherapy armamentarium. Concern over acute hypersensitivity reactions has resulted in an administration schedule consisting of a 24-hour infusion. We conducted a phase I trial of a 3-hour infusion of paclitaxel to determine whether a 3-hour infusion could be administered with relative safety, and to identify the maximal tolerated dose with and without granulocyte colony-stimulating factor (G-CSF) support. Thirty-five patients with advanced, untreatable malignancies received a 3- hour infusion of paclitaxel once every 3 weeks. Groups of three patients were entered at escalating dose levels in a traditional phase I design consisting of two parallel arms: arm A (without G-CSF) and arm B (with G-CSF). Dose levels of paclitaxel ranged from 210 mg/m2 to 300 mg/m2. Patients assigned to the G-CSF arm received 5 μg/kg/d subcutaneously starting on day 2. All patients were pretreated with dexamethasone, diphenhydramine, and ranitidine, and were monitored continuously for cardiac arrhythmias during the first treatment. The dose-limiting toxicity for paclitaxel without G-CSF was myelosuppression at the 250 mg/m2 dose level and with G-CSF was peripheral neuropathy at the 300 mg/m2 dose level. The mean absolute neutrophil count at the 250 mg/m2 dose level when administered with and without G-CSF support was 4,500/μL and 840/μL, respectively. Neuropathy appeared to be dose related and somewhat cumulative. One patient who previously received cisplatin developed a severe grade III peripheral neuropathy at the 300 mg/m2 dose level, which left her unable to use her hands and wheelchair bound; the peripheral neuropathy slowly resolved to a grade I level. Twenty- seven of III courses (24%) were associated with grade III arthralgias or myalgias, requiring narcotics for pain control. Prednisone was empirically started in 10 patients and found to be helpful in the control of these symptoms. One of 35 (2.9%) patients had a grade III anaphylactic reaction. No clinically significant cardiac arrhythmias were observed. Two previously treated patients (one with breast cancer and one with ovarian cancer) had a partial response. The maximum tolerated dose of paclitaxel administered as a 3-hour infusion was 210 mg/m2 without G-CSF and 250 mg/m2 with G-CSF. We conclude that with proper monitoring and premedication, paclitaxel can be safely administered in the outpatient setting without an increased incidence of hypersensitivity reactions or other side effects, with the possible exception of arthralgias. These results provide a significant improvement in convenience and cost to cancer patients.

Original languageEnglish (US)
Pages (from-to)9-14
Number of pages6
JournalSeminars in Oncology
Volume21
Issue number5 SUPPL. 8
StatePublished - 1994

Fingerprint

Granulocyte Colony-Stimulating Factor
Paclitaxel
Arm
Peripheral Nervous System Diseases
Maximum Tolerated Dose
Arthralgia
Cardiac Arrhythmias
Hypersensitivity
Diphenhydramine
Wheelchairs
Ranitidine
Premedication
Drug and Narcotic Control
Myalgia
Anaphylaxis
Prednisone
Ovarian Neoplasms
Dexamethasone
Cisplatin
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Schiller, J. H., Storer, B., Tutsch, K., Arzoomanian, R., Alberti, D., Feierabend, C., & Spriggs, D. (1994). A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. Seminars in Oncology, 21(5 SUPPL. 8), 9-14.

A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. / Schiller, J. H.; Storer, B.; Tutsch, K.; Arzoomanian, R.; Alberti, D.; Feierabend, C.; Spriggs, D.

In: Seminars in Oncology, Vol. 21, No. 5 SUPPL. 8, 1994, p. 9-14.

Research output: Contribution to journalArticle

Schiller, JH, Storer, B, Tutsch, K, Arzoomanian, R, Alberti, D, Feierabend, C & Spriggs, D 1994, 'A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor', Seminars in Oncology, vol. 21, no. 5 SUPPL. 8, pp. 9-14.
Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C et al. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. Seminars in Oncology. 1994;21(5 SUPPL. 8):9-14.
Schiller, J. H. ; Storer, B. ; Tutsch, K. ; Arzoomanian, R. ; Alberti, D. ; Feierabend, C. ; Spriggs, D. / A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. In: Seminars in Oncology. 1994 ; Vol. 21, No. 5 SUPPL. 8. pp. 9-14.
@article{f8e01a9d26be4326aec949729dd129a6,
title = "A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor",
abstract = "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a novel antitubulin agent derived from the bark of the Pacific yew tree, may be one of the most active single agents in our chemotherapy armamentarium. Concern over acute hypersensitivity reactions has resulted in an administration schedule consisting of a 24-hour infusion. We conducted a phase I trial of a 3-hour infusion of paclitaxel to determine whether a 3-hour infusion could be administered with relative safety, and to identify the maximal tolerated dose with and without granulocyte colony-stimulating factor (G-CSF) support. Thirty-five patients with advanced, untreatable malignancies received a 3- hour infusion of paclitaxel once every 3 weeks. Groups of three patients were entered at escalating dose levels in a traditional phase I design consisting of two parallel arms: arm A (without G-CSF) and arm B (with G-CSF). Dose levels of paclitaxel ranged from 210 mg/m2 to 300 mg/m2. Patients assigned to the G-CSF arm received 5 μg/kg/d subcutaneously starting on day 2. All patients were pretreated with dexamethasone, diphenhydramine, and ranitidine, and were monitored continuously for cardiac arrhythmias during the first treatment. The dose-limiting toxicity for paclitaxel without G-CSF was myelosuppression at the 250 mg/m2 dose level and with G-CSF was peripheral neuropathy at the 300 mg/m2 dose level. The mean absolute neutrophil count at the 250 mg/m2 dose level when administered with and without G-CSF support was 4,500/μL and 840/μL, respectively. Neuropathy appeared to be dose related and somewhat cumulative. One patient who previously received cisplatin developed a severe grade III peripheral neuropathy at the 300 mg/m2 dose level, which left her unable to use her hands and wheelchair bound; the peripheral neuropathy slowly resolved to a grade I level. Twenty- seven of III courses (24{\%}) were associated with grade III arthralgias or myalgias, requiring narcotics for pain control. Prednisone was empirically started in 10 patients and found to be helpful in the control of these symptoms. One of 35 (2.9{\%}) patients had a grade III anaphylactic reaction. No clinically significant cardiac arrhythmias were observed. Two previously treated patients (one with breast cancer and one with ovarian cancer) had a partial response. The maximum tolerated dose of paclitaxel administered as a 3-hour infusion was 210 mg/m2 without G-CSF and 250 mg/m2 with G-CSF. We conclude that with proper monitoring and premedication, paclitaxel can be safely administered in the outpatient setting without an increased incidence of hypersensitivity reactions or other side effects, with the possible exception of arthralgias. These results provide a significant improvement in convenience and cost to cancer patients.",
author = "Schiller, {J. H.} and B. Storer and K. Tutsch and R. Arzoomanian and D. Alberti and C. Feierabend and D. Spriggs",
year = "1994",
language = "English (US)",
volume = "21",
pages = "9--14",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 8",

}

TY - JOUR

T1 - A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor

AU - Schiller, J. H.

AU - Storer, B.

AU - Tutsch, K.

AU - Arzoomanian, R.

AU - Alberti, D.

AU - Feierabend, C.

AU - Spriggs, D.

PY - 1994

Y1 - 1994

N2 - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a novel antitubulin agent derived from the bark of the Pacific yew tree, may be one of the most active single agents in our chemotherapy armamentarium. Concern over acute hypersensitivity reactions has resulted in an administration schedule consisting of a 24-hour infusion. We conducted a phase I trial of a 3-hour infusion of paclitaxel to determine whether a 3-hour infusion could be administered with relative safety, and to identify the maximal tolerated dose with and without granulocyte colony-stimulating factor (G-CSF) support. Thirty-five patients with advanced, untreatable malignancies received a 3- hour infusion of paclitaxel once every 3 weeks. Groups of three patients were entered at escalating dose levels in a traditional phase I design consisting of two parallel arms: arm A (without G-CSF) and arm B (with G-CSF). Dose levels of paclitaxel ranged from 210 mg/m2 to 300 mg/m2. Patients assigned to the G-CSF arm received 5 μg/kg/d subcutaneously starting on day 2. All patients were pretreated with dexamethasone, diphenhydramine, and ranitidine, and were monitored continuously for cardiac arrhythmias during the first treatment. The dose-limiting toxicity for paclitaxel without G-CSF was myelosuppression at the 250 mg/m2 dose level and with G-CSF was peripheral neuropathy at the 300 mg/m2 dose level. The mean absolute neutrophil count at the 250 mg/m2 dose level when administered with and without G-CSF support was 4,500/μL and 840/μL, respectively. Neuropathy appeared to be dose related and somewhat cumulative. One patient who previously received cisplatin developed a severe grade III peripheral neuropathy at the 300 mg/m2 dose level, which left her unable to use her hands and wheelchair bound; the peripheral neuropathy slowly resolved to a grade I level. Twenty- seven of III courses (24%) were associated with grade III arthralgias or myalgias, requiring narcotics for pain control. Prednisone was empirically started in 10 patients and found to be helpful in the control of these symptoms. One of 35 (2.9%) patients had a grade III anaphylactic reaction. No clinically significant cardiac arrhythmias were observed. Two previously treated patients (one with breast cancer and one with ovarian cancer) had a partial response. The maximum tolerated dose of paclitaxel administered as a 3-hour infusion was 210 mg/m2 without G-CSF and 250 mg/m2 with G-CSF. We conclude that with proper monitoring and premedication, paclitaxel can be safely administered in the outpatient setting without an increased incidence of hypersensitivity reactions or other side effects, with the possible exception of arthralgias. These results provide a significant improvement in convenience and cost to cancer patients.

AB - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a novel antitubulin agent derived from the bark of the Pacific yew tree, may be one of the most active single agents in our chemotherapy armamentarium. Concern over acute hypersensitivity reactions has resulted in an administration schedule consisting of a 24-hour infusion. We conducted a phase I trial of a 3-hour infusion of paclitaxel to determine whether a 3-hour infusion could be administered with relative safety, and to identify the maximal tolerated dose with and without granulocyte colony-stimulating factor (G-CSF) support. Thirty-five patients with advanced, untreatable malignancies received a 3- hour infusion of paclitaxel once every 3 weeks. Groups of three patients were entered at escalating dose levels in a traditional phase I design consisting of two parallel arms: arm A (without G-CSF) and arm B (with G-CSF). Dose levels of paclitaxel ranged from 210 mg/m2 to 300 mg/m2. Patients assigned to the G-CSF arm received 5 μg/kg/d subcutaneously starting on day 2. All patients were pretreated with dexamethasone, diphenhydramine, and ranitidine, and were monitored continuously for cardiac arrhythmias during the first treatment. The dose-limiting toxicity for paclitaxel without G-CSF was myelosuppression at the 250 mg/m2 dose level and with G-CSF was peripheral neuropathy at the 300 mg/m2 dose level. The mean absolute neutrophil count at the 250 mg/m2 dose level when administered with and without G-CSF support was 4,500/μL and 840/μL, respectively. Neuropathy appeared to be dose related and somewhat cumulative. One patient who previously received cisplatin developed a severe grade III peripheral neuropathy at the 300 mg/m2 dose level, which left her unable to use her hands and wheelchair bound; the peripheral neuropathy slowly resolved to a grade I level. Twenty- seven of III courses (24%) were associated with grade III arthralgias or myalgias, requiring narcotics for pain control. Prednisone was empirically started in 10 patients and found to be helpful in the control of these symptoms. One of 35 (2.9%) patients had a grade III anaphylactic reaction. No clinically significant cardiac arrhythmias were observed. Two previously treated patients (one with breast cancer and one with ovarian cancer) had a partial response. The maximum tolerated dose of paclitaxel administered as a 3-hour infusion was 210 mg/m2 without G-CSF and 250 mg/m2 with G-CSF. We conclude that with proper monitoring and premedication, paclitaxel can be safely administered in the outpatient setting without an increased incidence of hypersensitivity reactions or other side effects, with the possible exception of arthralgias. These results provide a significant improvement in convenience and cost to cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0028072114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028072114&partnerID=8YFLogxK

M3 - Article

C2 - 7524159

AN - SCOPUS:0028072114

VL - 21

SP - 9

EP - 14

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5 SUPPL. 8

ER -